

## EDITORIALS

**Getting Closer to P-Selectin** D.I. Chasman and G. Paré (see article on page 1076) 1051

**Quality Control and Protein Microarrays** L.J. Kricka and S.R. Master (see article on page 1092) 1053

**Neopterin and Cardiovascular Disease: Growing Evidence for a Role in Patient Risk Stratification** P. Avanzas, R. Arroyo-Espliguero, and J.C. Kaski (see article on page 1135) 1056

## PERSPECTIVE

**Magnetism and MagnetoResistance: Attractive Prospects for Point-of-Care Testing?** L.J. Kricka and J.Y. Park 1058

## MINI-REVIEW

**Steroid Hormone Analysis by Tandem Mass Spectrometry** S.J. Soldin and O.P. Soldin 1061

## REVIEW

**Traceability in Laboratory Medicine** H.W. Vesper and L.M. Thienpont 1067

## ARTICLES

### MOLECULAR DIAGNOSTICS AND GENETICS

**SELP and SELPLG Genetic Variation Is Associated with Cell Surface Measures of SELP and SELPLG: The Atherosclerosis Risk in Communities Carotid MRI Study** K.A. Volcik, D. Catellier, A.R. Folsom, N. Matijevic, B. Wasserman, and E. Boerwinkle (see editorial on page 1051) 1076

**A Novel Approach to CFTR Mutation Testing by Pyrosequencing-Based Assay Panels Adapted to Ethnicities** J.K. Bickmann, W. Kamin, M. Wiebel, F. Häuser, J.J. Wenzel, C. Neukirch, M. Stuhmann, K.J. Lackner, and H. Rossmann 1083

### PROTEOMICS AND PROTEIN MARKERS

**Measurement and Quality Control Issues in Multiplex Protein Assays: A Case Study** A.A. Ellington, I.J. Kullo, K.R. Bailey, and G.G. Klee (see editorial on page 1053) 1092

**Quantification of Urinary Albumin by Using Protein Cleavage and LC-MS/MS** J.C. Seegmiller, D.R. Barnidge, B.E. Burns, T.S. Larson, J.C. Lieske, and R. Kumar 1100

**Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry** E. Kuhn, T. Addona, H. Keshishian, M. Burgess, D.R. Mani, R.T. Lee, M.S. Sabatine, R.E. Gerszten, and S.A. Carr 1108

**Cystatin C for Enhancement of Risk Stratification in Non-ST Elevation Acute Coronary Syndrome Patients with an Increased Troponin T** F. Windhausen, A. Hirsch, J. Fischer, P.M. van der Zee, G.T. Sanders, J.P. van Straalen, J.H. Cornel, J.G.P. Tijssen, F.W.A. Verheugt, and R.J. de Winter, for the Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators 1118

**Characterization of NT-proBNP in Human Urine** S.C. Palmer, Z.H. Endre, A.M. Richards, and T.G. Yandle 1126

### LIPIDS, LIPOPROTEINS, AND CARDIOVASCULAR RISK FACTORS

**Neopterin as a Predictor of Total and Cardiovascular Mortality in Individuals Undergoing Angiography in the Ludwigshafen Risk and Cardiovascular Health Study** T.B. Grammer, D. Fuchs, B.O. Boehm, B.R. Winkelmann, and W. Maerz (see editorial on page 1056) 1135

### AUTOMATION AND ANALYTICAL TECHNIQUES

**Liquid Chromatography–Tandem Mass Spectrometry Analysis of Folate and Folate Catabolites in Human Serum** R. Hannisdal, P.M. Ueland, and A. Svardal 1147

### ENDOCRINOLOGY AND METABOLISM

**Measurement of Aldosterone in Human Plasma by Semiautomated HPLC–Tandem Mass Spectrometry** P.J. Taylor, D.P. Cooper, R.D. Gordon, and M. Stowasser 1155

**Circulating Calcitriol Concentrations and Total Mortality** A. Zittermann, S.S. Schleithoff, S. Frisch, C. Götting, J. Kuhn, H. Koertke, K. Kleesiek, G. Tenderich, and R. Koerfer 1163

continued

## ARTICLES, *continued*

### HEMOSTASIS AND THROMBOSIS

- Dual Antiplatelet Drug Resistance Is a Risk Factor for Cardiovascular Events after Percutaneous Coronary Intervention B.T. Ivandic, M. Sausemuth, H. Ibrahim, E. Giannitsis, M. Gawaz, and H.A. Katus 1171

### DRUG MONITORING AND TOXICOLOGY

- Urinary Excretion of Buprenorphine, Norbuprenorphine, Buprenorphine-Glucuronide, and Norbuprenorphine-Glucuronide in Pregnant Women Receiving Buprenorphine Maintenance Treatment S.L. Kacinko, H.E. Jones, R.E. Johnson, R.E. Choo, M. Concheiro-Guisan, and M.A. Huestis 1177

- Intra- and Intersubject Whole Blood/Plasma Cannabinoid Ratios Determined by 2-Dimensional, Electron Impact GC-MS with Cryofocusing E.W. Schwilke, E.L. Karschner, R.H. Lowe, A.M. Gordon, J.L. Cadet, R.I. Herning, and M.A. Huestis 1188

- Ultraperformance Liquid Chromatography–Tandem Mass Spectrometry Assay for Iohexol in Human Serum T.M. Annesley and L.T. Clayton 1196

- Cheminformatic Methods for Predicting Interference in Drug of Abuse/Toxicology Immunoassays M.D. Krasowski, M.G. Siam, M. Iyer, A.F. Pizon, S. Giannoutsos, and S. Ekins 1203

## BRIEF COMMUNICATIONS

- Intravenous Administration of Low Molecular Weight and Unfractionated Heparin Elicits a Rapid Increase in Serum Pregnancy-Associated Plasma Protein A R. Tertti, S. Wittfooth, P. Porela, K.E. Airaksinen, K. Metsärinne, and K. Pettersson 1214

- High-Throughput Analysis of Sphingosine 1-Phosphate, Sphinganine 1-Phosphate, and Lysophosphatidic Acid in Plasma Samples by Liquid Chromatography–Tandem Mass Spectrometry M. Scherer, G. Schmitz, and G. Liebisch 1218

- SELDI-TOF Mass Spectrometry Evaluation of Variant Transthyretins for Diagnosis and Pathogenesis of Familial Amyloidotic Polyneuropathy M. Ueda, Y. Misumi, M. Mizuguchi, M. Nakamura, T. Yamashita, Y. Sekijima, K. Ota, S. Shinriki, H. Jono, S. Ikeda, O.B. Suhr, and Y. Ando 1223

## CLINICAL CASE STUDY

- A Patient with a Previous Diagnosis of Hemoglobin S/C Disease with an Unusually Severe Disease Course E.K. O’Keefe, M.M. Rhodes, and A. Woodworth 1228

## COMMENTARIES

- C. Brugnara 1231  
J. Hoyer 1232

## CITATION CLASSIC

- The Origins of Ion Spray Liquid Chromatography–Tandem Mass Spectrometry J.D. Henion 1234

## Q&A

- Mass Spectrometry in the Clinical Laboratory: How Have We Done, and Where Do We Need to Be? T. Annesley 1236

## LETTERS TO THE EDITOR

- Use of Serum Myoglobin Assays for Urine Myoglobin Measurements Can Cause False-Negative Results H. de Waard and P. van ’t Sant 1240

- Urinary  $\beta$ -Trace Protein as a New Renal Tubular Marker L.L. Vynckier, K.M.J. Floré, S.E. Delanghe, and J.R. Delanghe 1241

- Newborn Screening for Sickle Cell Disease through Use of Tandem Mass Spectrometry C. Turner, Y. Daniel, and R.N. Dalton 1243

- In Reply F. Boemer, O. Ketelslegers, J.-M. Minon, V. Bours, and R. Schoos 1244

- Analytical and Biological Variation of F<sub>2</sub>-Isoprostanes during the Menstrual Cycle R.W. Browne, M.S. Bloom, E.F. Schisterman, J. Wactawski-Wende, K. Hovey, M. Trevisan, and M. Gross 1245

*continued*

## LETTERS TO THE EDITOR, *continued*

- Serum 25-Hydroxyvitamin D Immunoassays: Recommendations for Correct Clinical Interpretation**  
C. Massart and J.-C. Souberbielle 1247
- Effect of a Variable Magnetic Field on Clinical Laboratory Testing** L.J. Kricka, M. Milone, S.R. Master, L.M. Shaw, D.S. Young, R. Fontanilla, T. Smith, J. Gardiner, D. Cardamone, M. Fleming, and D.G. Rhoads 1249
- More on Methanol-Associated Matrix Effects in Electrospray Ionization Mass Spectrometry**  
K.L. Napoli 1250

## CLINICAL CHEMIST


- Unveiling the Right Side: How to Win Wimbledon Championships: Creating Beklof and Vamos**  
E.P. Diamandis 1253
- What Is Your Guess?** M.L. Snyder and C.R. Fantz 1255
- Lily Robinson and Death Outside the Box: Recollections** 1256
- Clinical Chemistry's NIH Book Club Corner** 1257

## CORRECTIONS

- In Reply** M.P. Caulfield, S. Li, G. Lee, P.A. Blanche, W.A. Salameh, W.H. Benner, R.E. Reitz, and R.M. Krauss 1258
- A Multimarker Circulating DNA Assay for Assessing Prostate Cancer Patients' Blood** E. Sunami, M. Shinozaki, C.S. Higano, R. Wollman, T.B. Dorff, S.J. Tucker, S.R. Martinez, R. Mizuno, F.R. Singer, and D.S.B. Hoon 1258

## ACCENT®—CONTINUING EDUCATION CREDIT FOR READERS OF *CLINICAL CHEMISTRY*

For more information go to  
<http://apps.aacc.org/ccj/accent>



**ON THE COVER** The electrospray ionization (ESI) process. In 2002 analytical chemist John Fenn was awarded the Nobel Prize for his pioneering work in the development of this soft ionization method. ESI allows small (drugs) and large (peptides) molecules to be analyzed directly from a liquid phase such as HPLC using mass spectrometry (MS). In fact, Fenn's Nobel lecture was entitled "Electrospray Wings for Molecular Elephants." This issue of *Clinical Chemistry* includes a review and several research articles that highlight the use of ESI-MS for estrogens, buprenorphine, aldosterone, iohexol, lysophospholipids, folates, and albumin in biological fluids. See pages 1061, 1100, 1150, 1158, 1180, 1199, 1221. Reproduced with permission from TransTech Publications Inc. and Anatol Jaworek.

*Color figures for Reviews sponsored by Department of Laboratory Medicine, Children's Hospital Boston.*